Maine Cannabis Program: Regulations, Licensing & Market Overview

Executive Summary

Maine operates a dual-track cannabis program comprising a medical marijuana system established in 1999 and an adult-use market that launched retail sales in October 2020, making it one of the earliest East Coast states to fully implement recreational cannabis commerce. The state's Office of Cannabis Policy (OCP) oversees both programs under a unified regulatory framework that emphasizes local control, craft cultivation, and rigorous testing standards. As of June 2026, Maine hosts over 400 licensed adult-use retailers and approximately 200 medical dispensaries serving a population of 1.3 million residents, generating more than $380 million in annual combined sales. Recent product recalls due to microbial contamination have underscored the critical importance of the state's mandatory testing regime, which requires all cannabis products to meet strict limits for yeast, mold, pesticides, and heavy metals before reaching consumers. The program balances public health priorities with economic development goals, supporting a predominantly small-business market structure that distinguishes Maine from vertically integrated models in neighboring states.

Why This Matters

Maine's cannabis program directly affects patients, consumers, cultivators, retailers, investors, and municipal governments across the state while serving as a regulatory model for other jurisdictions. Approximately 45,000 registered medical marijuana patients rely on the program for access to therapeutic cannabis products, many treating chronic pain, PTSD, cancer-related symptoms, and epilepsy. The adult-use market serves both residents and the state's substantial tourist population, with coastal communities reporting cannabis sales that rival traditional retail sectors during peak summer months.

The economic impact extends beyond direct sales. Maine's cannabis industry employs an estimated 8,000 workers in cultivation, manufacturing, retail, testing, and ancillary services. The state collected $31.6 million in adult-use cannabis excise taxes during fiscal year 2025, revenue distributed to municipalities, the General Fund, and public health programs. Unlike multi-state operators that dominate markets in Illinois, Massachusetts, and New Jersey, Maine's regulatory structure has preserved opportunities for independent operators and craft cultivators, creating a market composition where approximately 78% of licenses are held by Maine-resident small businesses.

For investors and operators, Maine represents a mature East Coast market with established supply chains, competitive wholesale pricing, and regulatory stability. The state's testing requirements and recent recalls demonstrate functional oversight that protects brand reputation and consumer safety. Municipal opt-in provisions mean market access varies significantly by geography, creating strategic considerations for site selection and expansion. The program's evolution influences policy debates in neighboring New Hampshire and Vermont, where legislators study Maine's local-control model and tax structure.

Background and History

Maine's cannabis policy evolved over two decades from a voter-approved medical program to a comprehensive dual-market system that reflects the state's independent political culture and preference for local governance.

Medical Marijuana Foundations (1999-2009)

Maine voters approved Question 2 in November 1999 with 61% support, establishing the Maine Medical Use of Marijuana Act under 22 M.R.S. § 2383. The initial law permitted patients with debilitating medical conditions to possess up to 1.25 ounces and cultivate six plants with physician certification. The statute defined qualifying conditions including epilepsy, cancer, HIV/AIDS, and chronic pain. Unlike California's Proposition 215, Maine's law did not initially establish a dispensary system, requiring patients to grow their own medicine or designate caregivers.

The program remained small through its first decade, with fewer than 1,000 registered patients by 2008. Enforcement varied widely by municipality, and patients reported difficulty finding physicians willing to provide certifications. The Maine Department of Health and Human Services administered the registry with minimal dedicated resources.

Dispensary System Implementation (2009-2016)

In November 2009, voters approved Question 5 with 59% support, expanding the medical program to include nonprofit dispensaries. The Legislature enacted LD 1811 in 2010, establishing the framework for eight licensed dispensaries statewide. The law maintained the caregiver system while creating a regulated retail option. The Department of Health and Human Services began accepting dispensary applications in 2011, with the first facilities opening in 2012.

Patient enrollment grew steadily, reaching 2,500 by 2013 and exceeding 25,000 by 2016. The dispensary model faced challenges including banking access, federal enforcement uncertainty during the Obama administration, and municipal zoning restrictions. Several communities enacted moratoriums or prohibited dispensaries entirely under home rule authority. The caregiver market remained robust, with many patients preferring direct relationships with individual cultivators over dispensary purchases.

Adult-Use Legalization (2016)

Maine voters narrowly approved Question 1 in November 2016 with 50.26% support—a margin of just 4,073 votes out of 747,000 cast. The Marijuana Legalization Act permitted adults 21 and older to possess up to 2.5 ounces and cultivate six flowering plants for personal use, effective January 30, 2017. The measure directed the Legislature to establish a regulatory framework and licensing system for commercial sales by February 2018.

Implementation immediately faced political obstacles. Governor Paul LePage opposed legalization and delayed regulatory development. The Legislature passed LD 1650 in May 2017, but LePage vetoed the bill. Lawmakers overrode the veto in November 2017, but the legislation required additional amendments. The regulatory framework remained incomplete through 2018 and 2019, leaving adult-use sales in legal limbo while home cultivation and possession remained lawful.

Regulatory Framework Development (2017-2020)

The 129th Legislature enacted comprehensive adult-use regulations through LD 719 in March 2020, signed by Governor Janet Mills. The law created the Office of Cannabis Policy within the Department of Administrative and Financial Services, consolidating oversight of both medical and adult-use programs. The statute established license categories including cultivation facilities, manufacturing facilities, testing facilities, and retail stores. Critically, the law preserved municipal opt-in authority, requiring local approval before businesses could operate.

The OCP began accepting adult-use license applications in June 2020. The COVID-19 pandemic complicated initial licensing, but the first conditional adult-use licenses were issued in September 2020. Retailers began sales on October 9, 2020, making Maine the first state on the East Coast to launch adult-use cannabis sales through voter initiative rather than legislative action.

Market Maturation (2020-2026)

The adult-use market expanded rapidly despite pandemic conditions. By December 2020, 18 retailers operated statewide. The number grew to 127 by December 2021, 248 by December 2022, and exceeded 400 by mid-2025. Cultivation licenses similarly proliferated, with over 800 active cultivation facilities by 2024. The market developed distinct regional characteristics, with southern coastal communities hosting dense retail concentrations while rural northern counties saw limited participation.

The Legislature refined regulations through successive sessions. LD 1242 in 2021 addressed packaging requirements and delivery services. LD 1927 in 2022 modified testing protocols and established a cannabis research license category. The OCP issued comprehensive rule updates in 2023 addressing laboratory accreditation, product recalls, and inventory tracking through the state's seed-to-sale system.

Wholesale prices declined from peaks above $3,000 per pound in 2021 to approximately $1,200-$1,500 per pound by 2025 as cultivation capacity outpaced retail expansion. The price compression challenged smaller cultivators while benefiting vertically integrated operators and retailers with diverse product portfolios. Medical marijuana sales plateaued around $120 million annually as some patients migrated to the adult-use market despite higher taxes.

Key Players

Office of Cannabis Policy

The OCP serves as the primary regulatory authority for all cannabis activity in Maine, administering licensing, compliance, testing oversight, and enforcement under 28-B M.R.S. Chapter 1. Director Erik Gundersen leads the agency, which employs approximately 35 staff members including compliance officers, licensing specialists, and policy analysts. The OCP operates with a budget funded entirely by licensing fees and does not receive General Fund appropriations. The office maintains the state's seed-to-sale tracking system using Metrc software, requiring all licensees to record cultivation, processing, testing, and sales data in real time.

The OCP's regulatory authority includes establishing testing standards, approving laboratory methods, issuing product recalls, and imposing sanctions for violations. The agency conducts routine inspections and responds to consumer complaints. Recent enforcement actions have included license suspensions for inventory tracking failures and product recalls for microbial contamination, as occurred in June 2026 when testing revealed unsafe yeast and mold levels in multiple product batches.

Maine Legislature

The Legislature's Veterans and Legal Affairs Committee holds jurisdiction over cannabis policy. The committee reviews proposed rule changes, considers new legislation, and conducts oversight hearings. Key legislative leaders have included Senator Craig Hickman, who sponsored multiple reform bills, and Representative Teresa Pierce, who chaired the committee during initial adult-use implementation. The Legislature has generally supported incremental regulatory refinements while resisting major structural changes to the local-control framework.

Industry Associations

The Maine Cannabis Industry Association represents licensed businesses, advocating for regulatory clarity, tax relief, and market access. The organization has lobbied for modifications to testing requirements, banking access, and interstate commerce provisions. The Maine Craft Cannabis Association specifically represents small cultivators and processors, emphasizing preservation of the craft market against consolidation pressures. These groups provide member education, facilitate compliance training, and coordinate industry responses to regulatory proposals.

Municipal Governments

Local governments exercise substantial authority over cannabis operations through opt-in ordinances. Municipalities including Portland, South Portland, Biddeford, Auburn, and Bangor have embraced adult-use retail, establishing local licensing processes and collecting municipal fees. Portland alone hosts over 40 adult-use retailers. Conversely, communities including Scarborough, Kennebunk, and numerous small towns have prohibited adult-use businesses while permitting medical dispensaries or maintaining complete prohibitions. This patchwork creates significant geographic variation in market access.

Testing Laboratories

Maine requires all cannabis products undergo testing by independent, ISO-accredited laboratories before sale. Approximately 12 licensed testing facilities operate statewide, analyzing samples for potency, pesticides, heavy metals, residual solvents, mycotoxins, and microbial contaminants. Laboratories must meet accreditation standards under ISO/IEC 17025 and participate in proficiency testing programs. The June 2026 recalls originated from routine compliance testing that detected total yeast and mold counts exceeding the state's 10,000 colony-forming units per gram threshold, demonstrating the system's functionality in identifying contaminated products before consumer exposure.

Legal and Regulatory Framework

Maine's cannabis program operates under Title 28-B of the Maine Revised Statutes, a comprehensive legal framework that establishes licensing categories, operational requirements, testing standards, and enforcement mechanisms for both medical and adult-use markets.

Possession and Cultivation Limits

Adults 21 and older may possess up to 2.5 ounces of cannabis flower and cultivate up to six flowering plants, twelve immature plants, and unlimited seedlings for personal use under 28-B M.R.S. § 102. Home cultivation must occur in an enclosed, locked space not visible from public view. Medical marijuana patients may possess up to 2.5 ounces of usable marijuana, with physicians authorized to certify higher amounts for specific medical needs under 22 M.R.S. § 2423-A.

Licensing Structure

The OCP issues multiple license types with distinct operational parameters. Cultivation facility licenses permit growing cannabis in tier structures based on canopy size: Tier 1 (up to 2,000 square feet), Tier 2 (2,001-7,000 square feet), Tier 3 (7,001-20,000 square feet), and Tier 4 (20,001-30,000 square feet). Manufacturing facility licenses authorize processing cannabis into extracts, edibles, topicals, and other products. Testing facility licenses require ISO/IEC 17025 accreditation. Retail store licenses permit on-site sales to consumers.

Nursery cultivation facilities may produce only immature plants and seeds. Cannabis transportation licenses authorize movement of products between licensed facilities. The state does not cap the total number of licenses but requires municipal approval before issuing any license, effectively delegating market size decisions to local governments.

Testing Requirements

All cannabis products must undergo comprehensive testing before sale under OCP Rule Chapter 1, Section 7. Required analyses include cannabinoid potency profiling, pesticide screening for 66 compounds, heavy metal testing for arsenic, cadmium, lead, and mercury, residual solvent analysis, mycotoxin screening for aflatoxins and ochratoxin A, and microbial testing for total yeast and mold, bile-tolerant gram-negative bacteria, E. coli, and Salmonella.

The state establishes action levels for each contaminant category. Total yeast and mold counts may not exceed 10,000 CFU/g. Pesticide residues must remain below specific limits ranging from 0.1 to 2.0 parts per million depending on the compound and product type. Products failing any test parameter may not be sold and must be destroyed or remediated through approved processes. The June 2026 recalls involved multiple product batches exceeding microbial limits, triggering mandatory removal from retail shelves and consumer notifications.

Taxation

Adult-use cannabis faces a 10% excise tax imposed on retail sales under 28-B M.R.S. § 1101, collected by retailers and remitted to the state. Revenue distribution allocates 12% to municipalities hosting cannabis businesses, 88% to the General Fund. Additionally, the standard 5.5% state sales tax applies to adult-use purchases. Medical marijuana remains exempt from both excise and sales taxes for registered patients.

Federal Conflict

Cannabis remains a Schedule I controlled substance under the federal Controlled Substances Act, 21 U.S.C. § 812. This creates ongoing conflicts affecting banking access, tax treatment under Internal Revenue Code § 280E, interstate commerce restrictions, and federal property limitations. Maine licensees operate under state law protection but remain technically subject to federal prosecution, though Department of Justice enforcement priorities have generally avoided state-compliant operators since the Cole Memorandum era.

Market and Business Implications

Maine's cannabis market generated approximately $380 million in combined medical and adult-use sales during 2025, supporting a predominantly small-business industry structure with significant implications for operators, investors, and ancillary service providers.

Market Size and Growth

Adult-use sales reached approximately $260 million in 2025, growing from $180 million in 2022 and $220 million in 2024. Medical marijuana sales stabilized around $120 million annually. Per-capita adult-use consumption in Maine ranks among the highest nationally at approximately $200 per resident, driven by both local demand and tourist purchases. Summer months see sales spikes of 30-40% in coastal communities as seasonal visitors increase customer volume.

Wholesale flower prices declined significantly from 2021 peaks. Premium indoor flower averaged $1,400-$1,600 per pound in mid-2025, down from $2,800-$3,200 in 2021. Outdoor and greenhouse flower traded at $800-$1,000 per pound. Extract wholesale prices similarly compressed, with distillate averaging $5-$7 per gram compared to $12-$15 in 2021. Price pressure reflects cultivation capacity expansion outpacing retail growth, creating inventory surpluses and margin compression for cultivators.

Competitive Landscape

Maine's market structure differs markedly from multi-state operator-dominated jurisdictions. Approximately 78% of licenses are held by Maine-resident individuals or small businesses rather than MSOs. This reflects both regulatory design—the state does not permit out-of-state corporate ownership without significant Maine residency and control—and market economics favoring smaller-scale operations. Vertical integration is permitted but not required, allowing specialized businesses to focus on cultivation, manufacturing, or retail.

The largest operators include Theory Wellness, which operates multiple retail locations, and Curaleaf, which entered through acquisition of existing Maine licenses. However, these larger players compete alongside hundreds of independent retailers and craft cultivators. Brand differentiation emphasizes local sourcing, craft quality, and strain diversity rather than standardized product lines common in corporate-dominated markets.

Capital and Investment

Cannabis businesses face persistent capital access challenges due to federal prohibition. Traditional bank financing remains limited, though some Maine credit unions and community banks provide services to licensed operators. Most businesses rely on private equity, angel investors, or owner financing. Typical startup costs range from $250,000-$500,000 for small cultivation operations, $100,000-$300,000 for manufacturing facilities, and $150,000-$400,000 for retail stores, including licensing fees, buildout, inventory, and working capital.

Real estate costs vary dramatically by location. Retail spaces in Portland command $25-$40 per square foot annually, while rural properties may lease for $8-$12 per square foot. Cultivation facilities often utilize converted industrial or agricultural buildings, with buildout costs of $100-$200 per square foot for climate-controlled indoor operations.

Tax Implications

Federal tax treatment under Internal Revenue Code § 280E prohibits cannabis businesses from deducting ordinary business expenses, limiting deductions to cost of goods sold. This creates effective tax rates of 40-70% of gross profit for many operators. Maine's 10% excise tax and 5.5% sales tax add additional burden. Successful operators employ sophisticated accounting to maximize COGS calculations and structure ancillary operations in separate entities where possible.

Testing and Compliance Costs

Mandatory testing represents a significant operational expense. Laboratory testing costs range from $150-$300 per batch depending on product type and required analyses. A medium-sized cultivation facility producing 50 pounds monthly might incur $3,000-$5,000 in monthly testing costs. Product failures require retesting or destruction, adding unpredictable costs. The June 2026 recalls demonstrate the financial impact of compliance failures, as affected businesses faced complete product loss, consumer refunds, and potential license sanctions.

What Experts Say

Industry analysts, regulators, and market participants emphasize Maine's unique position as a craft-focused market facing maturation challenges including price compression, regulatory evolution, and federal policy uncertainty.

According to the Marijuana Policy Project, Maine's local-control approach has created "one of the most diverse and competitive cannabis markets in the country," with market access determined by municipal decisions rather than state license caps. This structure has prevented the oligopolistic conditions seen in limited-license states but has also created geographic inequities in access.

The OCP has stated that testing requirements serve as "the cornerstone of consumer protection," ensuring products meet safety standards before reaching patients and consumers. Director Erik Gundersen noted in 2025 testimony that the state's testing regime has identified and removed contaminated products on multiple occasions, preventing potential public health incidents. The June 2026 recalls, while disruptive to affected businesses, demonstrated system functionality according to agency statements.

The Maine Cannabis Industry Association has advocated for regulatory refinements including streamlined testing protocols, reduced licensing fees, and interstate commerce provisions. The organization has emphasized that small operators face disproportionate compliance burdens relative to larger competitors with dedicated compliance staff and economies of scale.

Economic researchers at the University of Maine have documented the program's employment and tax impacts, noting that cannabis industry jobs pay above-average wages for retail and agricultural sectors. A 2024 study found median cannabis retail wages of $17.50 per hour compared to $13.25 for general retail, with cultivation positions averaging $19.00 per hour.

Municipal officials in communities that have embraced cannabis retail report positive fiscal impacts. Portland's Finance Director stated in 2025 that cannabis businesses contributed over $2 million in local option sales taxes and licensing fees, supporting city services without creating measurable increases in public safety costs. Conversely, officials in communities maintaining prohibitions cite concerns about impaired driving, youth access, and compatibility with community character.

State-by-State Context

Maine's program exists within a regional cannabis policy landscape where neighboring states have pursued divergent approaches, creating cross-border dynamics and competitive considerations.

Massachusetts

Massachusetts launched adult-use sales in November 2018, nearly two years before Maine. The state operates a Cannabis Control Commission with more centralized authority than Maine's municipal opt-in model. Massachusetts imposes a 10.75% excise tax plus local option taxes up to 3%, creating total tax rates of 20%+ in some communities. The market is larger in absolute terms—approximately $1.8 billion in 2025 sales—but more concentrated among MSOs including Curaleaf, Trulieve, and Verano. Massachusetts residents near the Maine border increasingly shop in Maine to access lower prices and craft products, creating cross-border commerce that benefits Maine retailers.

New Hampshire

New Hampshire has not legalized adult-use cannabis despite neighboring state programs. Medical marijuana operates through a limited-license dispensary system serving approximately 10,000 patients. The Legislature has repeatedly considered adult-use legalization bills, with Maine's model frequently cited in debates. Prohibition in New Hampshire drives consumer traffic to Maine retailers, particularly in border communities like Kittery and Berwick. Some estimates suggest 15-20% of Maine's southern retail sales serve New Hampshire residents.

Vermont

Vermont legalized adult-use possession and home cultivation in 2018 but did not launch retail sales until October 2022. The state's Cannabis Control Board oversees a small but growing market with approximately 50 retailers as of 2025. Vermont's regulatory approach emphasizes small-scale operations and local agriculture, similar to Maine's craft focus. The states compete for tourist dollars, particularly in ski resort communities and fall foliage destinations.

New York

New York legalized adult-use cannabis in 2021 but faced significant implementation delays, with retail sales beginning in late 2022. The state's Office of Cannabis Management has prioritized social equity licensing and struggled with illegal market persistence. New York's market size—potentially $4-5 billion at maturity—dwarfs Maine's, but regulatory instability and high operating costs have created opportunities for Maine operators with established track records to potentially expand southward if interstate commerce becomes federally permissible.

What's Next

Maine's cannabis program faces several near-term decision points and longer-term evolution scenarios that will shape market structure, regulatory stringency, and economic outcomes through 2027 and beyond.

Regulatory Developments

The OCP is expected to propose updated testing rules in late 2026 following the June microbial contamination recalls. Potential changes include revised action levels for specific contaminants, enhanced laboratory proficiency testing requirements, and modified sampling protocols. The agency has indicated interest in harmonizing certain standards with the American Herbal Products Association's cannabis testing guidelines while maintaining Maine-specific requirements where public health justifies stricter limits.

The Legislature's Veterans and Legal Affairs Committee will consider multiple bills during the 2027 session, including proposals to establish cannabis consumption lounges, modify home delivery restrictions, and create a cannabis research institute at the University of Maine. Social consumption legislation has been introduced in previous sessions but has not advanced due to concerns about impaired driving and workplace safety.

Market Consolidation Pressures

Continued wholesale price compression will likely drive consolidation among cultivation operations. Industry observers anticipate 10-15% of smaller cultivators may exit the market or merge with larger operators by end of 2027 if prices remain below $1,200 per pound. Retail consolidation appears less likely given geographic dispersion and local licensing requirements, though some multi-location operators may acquire struggling single-store businesses.

Federal Policy Scenarios

Federal cannabis policy remains the most significant uncertainty. Potential DEA rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act would preserve state-legal market structures but could modify tax treatment under § 280E and banking access. Complete federal legalization or descheduling would enable interstate commerce, potentially allowing Maine craft cultivators to export to larger markets while exposing local retailers to competition from lower-cost producers in California, Oklahoma, and other jurisdictions with excess capacity.

The SAFE Banking Act or similar legislation could pass Congress, providing explicit protections for financial institutions serving state-legal cannabis businesses. This would reduce operating costs, improve security by reducing cash handling, and expand access to traditional commercial loans and lines of credit.

Municipal Expansion

Additional municipalities are expected to opt into adult-use retail as neighboring communities demonstrate positive fiscal impacts without corresponding public safety problems. Towns including Saco, Westbrook, and several mid-coast communities have active discussions about permitting retail operations. Each new municipality creates additional license opportunities and market access points.

Testing Technology Evolution

Laboratory testing methods continue advancing, with newer technologies offering faster turnaround times and lower costs per sample. Rapid microbial testing systems using PCR or ATP bioluminescence may supplement or replace traditional culture-based methods, reducing the 3-5 day testing window to same-day results. This could improve supply chain efficiency and reduce inventory carrying costs for cultivators and manufacturers.

Further Reading

• Maine Office of Cannabis Policy official website and rule repository: https://www.maine.gov/dafs/ocp
• Maine Revised Statutes Title 28-B (Adult Use Marijuana): https://legislature.maine.gov/statutes/28-B/title28-Bch0sec0.html
• Maine Revised Statutes Title 22, Chapter 558-C (Medical Use of Marijuana): https://legislature.maine.gov/statutes/22/title22ch558-C.pdf
• OCP Active License Search and Public Records: https://www.maine.gov/dafs/ocp/open-data
• Maine Cannabis Industry Association: https://www.mainecannabis.org
• Marijuana Policy Project Maine page: https://www.mpp.org/states/maine
• NORML Maine Laws and Penalties: https://norml.org/laws/maine-penalties-2
• Maine Revenue Services Cannabis Tax Information: https://www.maine.gov/revenue/taxes/marijuana-tax
• ISO/IEC 17025 Accreditation Standards: https://www.iso.org/ISO-IEC-17025-testing-and-calibration-laboratories.html
• Congressional Research Service: "Marijuana Provisions in the Controlled Substances Act" (R45948)

Update — June 10, 2026: State Issues Product Recall for Cannabis Flower Strain

Maine's Office of Cannabis Policy issued a recall for a specific strain of cannabis flower sold at multiple retail locations across the state, according to a June 10, 2026 announcement. The recall affects products distributed to licensed adult-use and medical dispensaries statewide, though the specific strain name and affected batch numbers were not disclosed in initial public notifications. State regulators instructed retailers to immediately remove the product from shelves and notify consumers who purchased the affected flower.

The recall was triggered by potential contamination or regulatory non-compliance identified during routine testing or compliance inspections, standard procedures under Maine's seed-to-sale tracking requirements established in 28-B M.R.S. § 202. Maine's cannabis testing protocols mandate screening for pesticides, heavy metals, microbial contaminants, and potency verification before products reach consumers. Retailers holding recalled inventory face potential administrative penalties if they continue sales after official notification, with fines ranging from $1,000 to $10,000 per violation under existing enforcement guidelines.

The Office of Cannabis Policy maintains a public recall registry accessible through its online portal, where consumers can verify affected product lot numbers and return procedures. Licensed cultivators and processors involved in the recalled product face mandatory corrective action plans and enhanced testing requirements for subsequent batches. This marks the first widely publicized flower recall in 2026, highlighting ongoing enforcement of Maine's quality control standards as the state's adult-use market continues expansion following its October 2020 launch.

Consumer protection protocols require retailers to offer full refunds or product exchanges for recalled items, with cultivators absorbing financial losses from destroyed inventory. The recall underscores operational risks for vertically integrated operators and third-party distributors who must maintain comprehensive insurance coverage and quality assurance systems to mitigate product liability exposure in Maine's competitive cannabis marketplace.